TABLE 3.
TEAEs occurring in ≥5% of patients (by preferred term) in the total lanadelumab group (excluding hereditary angioedema attacks)
| Placebo | Lanadelumab | ||||
|---|---|---|---|---|---|
| 150 mg q4wks | 300 mg q4wks | 300 mg q2wks | Total | ||
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| Days 0‐69 | |||||
| Injection site pain | 12 (29.3) | 12 (42.9) | 9 (31.0) | 13 (48.1) | 34 (40.5) |
| Headache | 8 (19.5) | 1 (3.6) | 4 (13.8) | 6 (22.2) | 11 (13.1) |
| Viral upper respiratory tract infection | 4 (9.8) | 2 (7.1) | 3 (10.3) | 2 (7.4) | 7 (8.3) |
| Injection site erythema | 1 (2.4) | 2 (7.1) | 2 (6.9) | 2 (7.4) | 6 (7.1) |
| Days 70‐182 | |||||
| Injection site pain | 8 (21.6) | 9 (32.1) | 7 (25.0) | 7 (26.9) | 23 (28.0) |
| Viral upper respiratory tract infection | 9 (24.3) | 3 (10.7) | 5 (17.9) | 9 (34.6) | 17 (20.7) |
| Headache | 1 (2.7) | 3 (10.7) | 3 (10.7) | 7 (26.9) | 13 (15.9) |
| Injection site erythema | 0 | 4 (14.3) | 1 (3.6) | 1 (3.8) | 6 (7.3) |